Dysbiosis and immunothrombosis - How platelets and the gut microbiome interact

Platelets are classically recognised for their role in haemostasis and thrombosis. They are now increasingly recognised as modulators of the immune system, referred to as immunothrombosis, and are thought to be closely associated with the gut microbiome. The gut microbiome shapes platelet phenotype through receptor-mediated sensing of microbial ligands and circulating metabolite-driven priming. Dysbiosis and barrier disruption increase systemic exposure to microbial-associated molecular patterns (MAMPs) which, in turn, engage platelet and vascular pattern-recognition receptors. Prothrombotic metabolites such as trimethylamine N-oxide has also been shown to modulate platelet activation by amplifying calcium-dependent activation and downstream inflammatory crosstalk. Other metabolites, such as phenylacetylglutamine, have been shown to increase platelet activation through adrenergic receptor-mediated pathways. In contrast, short-chain fatty acids may reduce this thromboinflammatory platelet phenotypes through anti-inflammatory signalling and potential effects on megakaryopoiesis and platelet reactivity. Therapeutic options that target these pathways between platelets and the microbiota have been explored. Examples include dietary modifications and microbiome-based interventions. Yet, whilst promising, significant gaps remain in understanding the long-term impacts of these strategies on platelet behaviour and overall disease outcomes.